{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-21-012334","form_type":"8-K","ticker":"IMRX","cik":"0001790340","company_name":"Immuneering Corp","filed_at":"2021-09-09T23:59:59+00:00","discovered_at":"2026-05-14T18:04:19.684183+00:00","generated_at":"2026-06-29T04:54:05.361593+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Immuneering Q2 net loss $7.9M; IPO raised $129.4M; IMM-1-104 IND expected Q1 2022","bullets":["Net loss of $7.9M ($1.61/share) vs $3.6M ($0.73/share) in Q2 2020.","Cash $50.2M at June 30, 2021; excludes $118.3M net IPO proceeds from August 2021.","R&D expenses $7.0M, up from $3.2M YoY on preclinical costs and personnel.","Completed upsized IPO of 8.625M shares at $15.00/share for $129.4M gross.","IND filing for IMM-1-104 (RAF-MEK inhibitor) planned for Q1 2022; Phase 1 start H1 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-21-012334","json":"https://secwatch.observer/filing/0001558370-21-012334.json","markdown":"https://secwatch.observer/filing/0001558370-21-012334.md","text":"https://secwatch.observer/filing/0001558370-21-012334.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1790340/000155837021012334/0001558370-21-012334-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1790340/000155837021012334/imrx-20210909x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T04:54:05.361593+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}